KRROHealthcare · BiotechnologyKRRO Stock Forecast: Korro Bio, Inc. Price Predictions for 2026-2027
The 11 Wall Street analysts covering Korro Bio, Inc. hold a median 12-month price target of $22 — +107.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 38 of 100 as at 1 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
KRRO stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Korro Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (91): Reported profit is backed by cash, and the company is not expanding recklessly.
Volatility (5): The share price moves around a lot.
The rank is the raw material. Whether the rules would actually own Korro Bio, Inc. — and when they’d sell — is the membership.
KRRO stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on KRRO, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
The green dot is the last close — the median target sits +107.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 19 May 2026 | HC Wainwright & Co. | Maintains | Buy | $20 → $15 |
| 18 May 2026 | Citigroup | Initiates | Buy | $21 |
| 13 Mar 2026 | Cantor Fitzgerald | Maintains | Overweight | — |
| 13 Mar 2026 | Raymond James | Upgrade | Outperform | — |
| 19 Feb 2026 | Clear Street | Upgrade | Buy | — |
| 17 Feb 2026 | William Blair | Upgrade | Outperform | — |
| 29 Jan 2026 | Chardan Capital | Upgrade | Buy | — |
| 29 Jan 2026 | HC Wainwright & Co. | Upgrade | Buy | — |
| 29 Jan 2026 | Piper Sandler | Upgrade | Overweight | — |
| 28 Jan 2026 | Cantor Fitzgerald | Upgrade | Overweight | — |
| 28 Jan 2026 | Oppenheimer | Upgrade | Outperform | — |
| 14 Nov 2025 | Jones Trading | Downgrade | Hold | — |
| 13 Nov 2025 | Cantor Fitzgerald | Downgrade | Neutral | — |
| 13 Nov 2025 | Chardan Capital | Downgrade | Neutral | — |
| 13 Nov 2025 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 13 Nov 2025 | RBC Capital | Downgrade | Sector Perform | — |
| 13 Nov 2025 | William Blair | Downgrade | Market Perform | — |
| 31 Oct 2025 | Clear Street | Initiates | Buy | — |
| 13 Aug 2025 | Chardan Capital | Maintains | Buy | — |
| 13 Aug 2025 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
KRRO analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Korro Bio, Inc. (KRRO) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −0.8×
- Price / sales
- 38.9×
- Price / book
- 1.3×
- EV / EBITDA
- −1.0×
Cheaper than 81% of US stocks
Cheaper than 6% of US stocks
Cheaper than 65% of US stocks
Cheaper than 68% of US stocks
- Revenue growth (YoY)
- −100.0%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- −2154.0%
- Net margin
- 0.0%
Higher than 1% of US stocks
Higher than 4% of US stocks
Higher than 30% of US stocks
- Return on equity
- −87.8%
- Return on assets
- −26.8%
- Dividend yield
- —
Higher than 15% of US stocks
Higher than 16% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
KRRO vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KRRO appears on the weeks it earns a place.
Frequently asked questions about KRRO stock
What is the KRRO stock price forecast for 2026-2027?
The 11 Wall Street analysts covering Korro Bio, Inc. have a median 12-month price target of $22, with estimates ranging from $8 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is KRRO stock a buy right now?
Of the 11 analysts covering Korro Bio, Inc., 10 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Korro Bio, Inc. 38 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank KRRO?
As at 1 Aug 2026, Korro Bio, Inc. ranks 38 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (91 of 100).
Will KRRO stock go up?
No one can know that. What the data says: the median 12-month target from 11 analysts implies +107.3% from the last close, and Ticker Nerd's factor model ranks Korro Bio, Inc. 38 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the KRRO stock forecast for 2030?
No analyst covering Korro Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KRRO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $30 over the next 12 months.
What does Korro Bio, Inc. do?
Korro Bio Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts.
About Korro Bio, Inc.
Korro Bio Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts. The company develops genetic medicines that utilize RNA editing to treat rare and highly prevalent diseases. Its proprietary Oligonucleotide Promoted Editing of RNA (OPERA) platform recruits endogenous enzymes like ADAR to enable precise, transient single-base edits on RNA transcripts, repairing disease-causing mutations or modulating protein function without altering DNA. This oligonucleotide-based approach leverages established delivery methods such as GalNAc conjugation for liver targeting. Korro Bio Inc.'s lead program, KRRO-110, targets Alpha-1 Antitrypsin Deficiency (AATD), a genetic disorder causing lung and liver damage, and is in Phase 1/2 clinical trials. The company is also advancing KRRO-121 for hyperammonemia associated with urea cycle disorders and hepatic encephalopathy, along with programs in cardiometabolic diseases through a collaboration with Novo Nordisk, and explorations in Parkinson's disease and amyotrophic lateral sclerosis. Korro Bio Inc. focuses on liver-targeted and other tissue-specific therapies, positioning RNA editing as a tunable alternative in genetic medicine.
CEO Dr. Ram Aiyar MBA, Ph.D. · 49 employees · United States · https://www.korrobio.com